STOCK TITAN

Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) announced it will release its third-quarter financial results for the period ending September 30, 2020, on November 5, 2020, before market opening. A conference call to discuss these results and business updates will take place at 9:00 a.m. ET on the same day, accessible via phone and webcast. The call will be archived online for later access. Akebia is committed to improving the lives of those with kidney disease and has been operational since 2007, headquartered in Cambridge, Massachusetts.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Oct. 26, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020 before the opening of the financial markets.

Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, November 5, 2020 to discuss its third quarter financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 2860285. The call will also be webcast LIVE and can be accessed via the Investors section of the Company's website at http://ir.akebia.com.

A replay of the conference call will be available two hours after the completion of the call through November 11, 2020. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 2860285. An online archive of the conference call can be accessed via the Investors section of the Company's website at http://ir.akebia.com.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Investor Contact
Kristen K. Sheppard, Esq
ir@akebia.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-third-quarter-2020-financial-results-and-discuss-recent-business-highlights-301159465.html

SOURCE Akebia Therapeutics

FAQ

When will Akebia Therapeutics release its third-quarter financial results?

Akebia Therapeutics will release its third-quarter financial results on November 5, 2020, before the market opens.

What time is the conference call for Akebia Therapeutics' financial results?

The conference call for Akebia Therapeutics' financial results will be held at 9:00 a.m. ET on November 5, 2020.

How can I access the conference call for Akebia Therapeutics?

You can access the conference call by dialing (877) 458-0977 domestically or (484) 653-6724 internationally, using conference ID number 2860285. It will also be available via webcast on the company's website.

Is there a replay available for the Akebia Therapeutics conference call?

Yes, a replay of the conference call will be available two hours after its completion until November 11, 2020.

What is the purpose of Akebia Therapeutics?

Akebia Therapeutics is focused on developing and commercializing therapeutics to improve the lives of people impacted by kidney disease.

Akebia Therapeutics, Inc.

NASDAQ:AKBA

AKBA Rankings

AKBA Latest News

AKBA Stock Data

390.54M
207.87M
2.09%
27.29%
7.05%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE